Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAmanda L. KongBFBoris Fishman

Discussion

Loading...

Member takes

Overview

Real-world study reveals treatment patterns and safety profiles of antineoplastic agents for BPDCN patients, indicating systematic unmet needs.

Key Points

  • This research aims to evaluate the treatment landscape and safety outcomes for patients with BPDCN in the US using real-world data.
  • Conducted a retrospective cohort study using Optum Market Clarity® records.
  • Included BPDCN patients diagnosed between 2015 and 2024 with continuous health plan enrollment.
  • Assessed treatment patterns and adverse events based on ICD-10 codes.
  • Included 795 newly diagnosed BPDCN patients with a median follow-up of 30 months.
  • CPD accounted for 53% of patients with prior hematologic malignancies, impacting treatment outcomes.
  • Capillary leak syndrome occurred in 37% of patients treated with tagraxofusp.

Cite This Study

Kong et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d39ehttps://doi.org/10.1182/blood-2025-4605
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Poor survival and temporal trends in blastic plasmacytoid dendritic cell neoplasm: A SEER 2000–2022 analysis2025
  2. 2Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes2025 · 1 citations
  3. 3Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature2025
  4. 4Real-World Management of Blastic Plasmacytoid Dendritic Cell Neoplasm at an Academic Center with a Broad Regional Referral Base2025
  5. 5Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study2025 · 1 citations